vs
Side-by-side financial comparison of NATIONAL FUEL GAS CO (NFG) and UNITED THERAPEUTICS Corp (UTHR). Click either name above to swap in a different company.
UNITED THERAPEUTICS Corp is the larger business by last-quarter revenue ($790.2M vs $637.9M, roughly 1.2× NATIONAL FUEL GAS CO). UNITED THERAPEUTICS Corp runs the higher net margin — 46.1% vs 28.5%, a 17.6% gap on every dollar of revenue. On growth, NATIONAL FUEL GAS CO posted the faster year-over-year revenue change (24.1% vs 7.4%). UNITED THERAPEUTICS Corp produced more free cash flow last quarter ($173.3M vs $-2.7M). Over the past eight quarters, UNITED THERAPEUTICS Corp's revenue compounded faster (8.0% CAGR vs 6.9%).
National Fuel Gas Company is a diversified energy company with $6.2 billion in assets distributed among the following five operating segments: Exploration and Production, Pipeline and Storage, Gathering, Utility, and Energy Marketing. National Fuel Gas was incorporated in 1902 and is based in Williamsville, New York.
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; ...
NFG vs UTHR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $637.9M | $790.2M |
| Net Profit | $181.6M | $364.3M |
| Gross Margin | 86.6% | 86.9% |
| Operating Margin | 43.3% | 45.1% |
| Net Margin | 28.5% | 46.1% |
| Revenue YoY | 24.1% | 7.4% |
| Net Profit YoY | 303.8% | 20.9% |
| EPS (diluted) | $1.98 | $7.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $637.9M | $790.2M | ||
| Q3 25 | $443.1M | $799.5M | ||
| Q2 25 | $527.4M | $798.6M | ||
| Q1 25 | $734.8M | $794.4M | ||
| Q4 24 | $513.8M | $735.9M | ||
| Q3 24 | $310.0M | $748.9M | ||
| Q2 24 | $338.6M | $714.9M | ||
| Q1 24 | $558.7M | $677.7M |
| Q4 25 | $181.6M | $364.3M | ||
| Q3 25 | $107.3M | $338.7M | ||
| Q2 25 | $149.8M | $309.5M | ||
| Q1 25 | $216.4M | $322.2M | ||
| Q4 24 | $45.0M | $301.3M | ||
| Q3 24 | $-167.6M | $309.1M | ||
| Q2 24 | $-54.2M | $278.1M | ||
| Q1 24 | $166.3M | $306.6M |
| Q4 25 | 86.6% | 86.9% | ||
| Q3 25 | — | 87.4% | ||
| Q2 25 | 94.7% | 89.0% | ||
| Q1 25 | 81.6% | 88.4% | ||
| Q4 24 | 87.3% | 89.7% | ||
| Q3 24 | — | 88.9% | ||
| Q2 24 | 98.5% | 89.1% | ||
| Q1 24 | 81.0% | 89.2% |
| Q4 25 | 43.3% | 45.1% | ||
| Q3 25 | 40.6% | 48.6% | ||
| Q2 25 | 43.7% | 45.6% | ||
| Q1 25 | 43.2% | 48.2% | ||
| Q4 24 | 16.8% | 48.6% | ||
| Q3 24 | -63.4% | 45.8% | ||
| Q2 24 | -15.2% | 44.7% | ||
| Q1 24 | 44.9% | 52.6% |
| Q4 25 | 28.5% | 46.1% | ||
| Q3 25 | 24.2% | 42.4% | ||
| Q2 25 | 28.4% | 38.8% | ||
| Q1 25 | 29.4% | 40.6% | ||
| Q4 24 | 8.8% | 40.9% | ||
| Q3 24 | -54.1% | 41.3% | ||
| Q2 24 | -16.0% | 38.9% | ||
| Q1 24 | 29.8% | 45.2% |
| Q4 25 | $1.98 | $7.66 | ||
| Q3 25 | $1.18 | $7.16 | ||
| Q2 25 | $1.64 | $6.41 | ||
| Q1 25 | $2.37 | $6.63 | ||
| Q4 24 | $0.49 | $6.23 | ||
| Q3 24 | $-1.81 | $6.39 | ||
| Q2 24 | $-0.59 | $5.85 | ||
| Q1 24 | $1.80 | $6.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $271.4M | $2.9B |
| Total DebtLower is stronger | $2.7B | — |
| Stockholders' EquityBook value | $3.6B | $7.1B |
| Total Assets | $9.2B | $7.9B |
| Debt / EquityLower = less leverage | 0.75× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $271.4M | $2.9B | ||
| Q3 25 | $43.2M | $2.8B | ||
| Q2 25 | $39.3M | $3.0B | ||
| Q1 25 | $40.0M | $3.3B | ||
| Q4 24 | $48.7M | $3.3B | ||
| Q3 24 | $38.2M | $3.3B | ||
| Q2 24 | $81.4M | $3.0B | ||
| Q1 24 | $50.8M | $2.7B |
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.7B | — | ||
| Q2 25 | $2.7B | — | ||
| Q1 25 | $2.7B | — | ||
| Q4 24 | $2.7B | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.7B | — | ||
| Q1 24 | $2.4B | — |
| Q4 25 | $3.6B | $7.1B | ||
| Q3 25 | $3.1B | $6.6B | ||
| Q2 25 | $3.0B | $7.2B | ||
| Q1 25 | $2.8B | $6.8B | ||
| Q4 24 | $-76.2M | $6.4B | ||
| Q3 24 | $-15.5M | $6.1B | ||
| Q2 24 | $5.0M | $5.7B | ||
| Q1 24 | $75.3M | $5.3B |
| Q4 25 | $9.2B | $7.9B | ||
| Q3 25 | $8.7B | $7.4B | ||
| Q2 25 | $8.4B | $7.9B | ||
| Q1 25 | $8.5B | $7.7B | ||
| Q4 24 | $8.3B | $7.4B | ||
| Q3 24 | $8.3B | $7.1B | ||
| Q2 24 | $8.5B | $6.7B | ||
| Q1 24 | $8.7B | $6.5B |
| Q4 25 | 0.75× | — | ||
| Q3 25 | 0.87× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | 0.99× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 532.10× | — | ||
| Q1 24 | 31.68× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $274.9M | $346.2M |
| Free Cash FlowOCF − Capex | $-2.7M | $173.3M |
| FCF MarginFCF / Revenue | -0.4% | 21.9% |
| Capex IntensityCapex / Revenue | 43.5% | 21.9% |
| Cash ConversionOCF / Net Profit | 1.51× | 0.95× |
| TTM Free Cash FlowTrailing 4 quarters | $204.8M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $274.9M | $346.2M | ||
| Q3 25 | $237.8M | $562.1M | ||
| Q2 25 | $388.4M | $191.7M | ||
| Q1 25 | $253.8M | $461.2M | ||
| Q4 24 | $220.1M | $341.2M | ||
| Q3 24 | $197.9M | $377.2M | ||
| Q2 24 | $281.8M | $232.2M | ||
| Q1 24 | $315.3M | $376.5M |
| Q4 25 | $-2.7M | $173.3M | ||
| Q3 25 | $-47.8M | $351.6M | ||
| Q2 25 | $195.3M | $129.5M | ||
| Q1 25 | $59.9M | $386.3M | ||
| Q4 24 | $-20.3M | $254.5M | ||
| Q3 24 | $-49.1M | $300.7M | ||
| Q2 24 | $79.5M | $187.1M | ||
| Q1 24 | $80.3M | $338.3M |
| Q4 25 | -0.4% | 21.9% | ||
| Q3 25 | -10.8% | 44.0% | ||
| Q2 25 | 37.0% | 16.2% | ||
| Q1 25 | 8.2% | 48.6% | ||
| Q4 24 | -4.0% | 34.6% | ||
| Q3 24 | -15.8% | 40.2% | ||
| Q2 24 | 23.5% | 26.2% | ||
| Q1 24 | 14.4% | 49.9% |
| Q4 25 | 43.5% | 21.9% | ||
| Q3 25 | 64.4% | 26.3% | ||
| Q2 25 | 36.6% | 7.8% | ||
| Q1 25 | 26.4% | 9.4% | ||
| Q4 24 | 46.8% | 11.8% | ||
| Q3 24 | 79.7% | 10.2% | ||
| Q2 24 | 59.7% | 6.3% | ||
| Q1 24 | 42.1% | 5.6% |
| Q4 25 | 1.51× | 0.95× | ||
| Q3 25 | 2.21× | 1.66× | ||
| Q2 25 | 2.59× | 0.62× | ||
| Q1 25 | 1.17× | 1.43× | ||
| Q4 24 | 4.89× | 1.13× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 0.83× | ||
| Q1 24 | 1.90× | 1.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NFG
| Natural Gas Production | $302.5M | 47% |
| Natural Gas Residential Sales | $198.0M | 31% |
| Pipeline And Storage | $69.2M | 11% |
| Natural Gas Commercial Sales | $27.9M | 4% |
| Natural Gas Storage | $25.1M | 4% |
| Other | $4.1M | 1% |
| Natural Gas Midstream | $2.8M | 0% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
